Specialized in high-impact therapeutic areas
Iterative Health is focused on accelerating clinical trials across gastrointestinal (GI) hepatology, obesity, and cardiology by empowering our global site network built for industry-leading speed, enrollment, and quality.
Comprehensive clinical trial capabilities
Clinical partnerships
Sponsors and partners
Capabilities at a glance
Gastroenterology (GI)
Gastroenterology has been central to Iterative Health since our founding and it remains the cornerstone of our scientific and operational expertise, spanning the full spectrum of GI disease including chronic conditions like inflammatory bowel disease (IBD), autoimmune disorders like Celiac disease, and rare diseases like Familial Adenomatous Polyposis (FAP). We support complex and high-stakes GI clinical development programs through a global site network with an industry-leading track record in activation speed and enrollment performance.
Our expertise and experience in GI clinical trials span studies involving individuals with:
As a gastroenterologist, principal investigator, and former leader in immunology global development at Eli Lilly, I've seen firsthand how central clinicians are to high-performing research embedded within quality patient community care. With the right operational support, specialized training, and mentorship in place, our sites don't just execute trials - they accelerate new treatments that advance patients' health.
Charles C. Owen, Jr., MD, MBA, FACP, AGAF VP, GI MedicalIterative Health
Hepatology
Hepatology represents one of the most significant areas of unmet clinical need in medicine today, driven by the rising global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, metabolic dysfunction-associated steatohepatitis (MASH). With limited approved therapies and a patient population that is often underdiagnosed and understaged, the demand for well-executed clinical trials has never been greater. Through a global network of trained Principal Investigators, community-embedded research sites, and robust operational infrastructure, Iterative Health is purpose-built to deliver hepatology trials with excellence at scale.
Our expertise and experience in hepatology clinical trials span studies involving individuals with:
Obesity
As the obesity pipeline accelerates, sponsors require site networks that can reliably engage diverse patient populations at scale and deliver on enrollment without compromise. Iterative Health brings specialized obesity training and operational support, many obesity-accredited Principal Investigators across our network, and the broad patient reach and cross-specialty depth spanning gastroenterology, hepatology, and cardiology to execute these programs with confidence.
Our expertise and experience in obesity clinical trials span studies involving individuals with:
In hepatology and obesity clinical trials, success comes down to three things: accessing the right patients, having investigators who are truly invested, and delivering the operational excellence at scale that sponsors depend on. We have built that foundation at Iterative Health, and I am proud to help lead it forward.
Nadege Gunn, MD, CPI, DABOM, FAASLD Chief Medical Officer, Hepatology & ObesityIterative Health
Cardiology
Cardiovascular disease is the leading cause of death worldwide, yet the majority of trials continue to draw from academic centers that represent a fraction of the patients living with these conditions. Iterative Health's leading site network embedded in community practices reaches engaged patients through physicians they already know and trust, backed by specialized training and dedicated operational support that equips sites to perform at the highest level.
Our expertise and experience in cardiology clinical trials span studies involving individuals with:
Innovation in cardiovascular medicine shouldn’t be limited to a few academic centers. By expanding community-based research across USHV, we’re ensuring more patients have access to clinical trials and breakthrough therapies close to home, where trusted relationships with their physicians already exist.
Thomas Waggoner, DO, MD, RPVI, FACC, FSCAI, FSVM, RPVIStructural Cardiologist and Medical Director for Clinical Research at Pima Heart & Vascular
Bring your next trialto a network built for it
Whether you're planning a Phase 1b or a global Phase 3, our specialized site network delivers the speed, scale, and quality your program needs.
Get in touch